Feasibility and acceptability of using bronchial hyperresponsiveness to manage asthma in primary care: a pilot study.
Prim Care Respir J
; 21(1): 28-34, 2012 Mar.
Article
em En
| MEDLINE
| ID: mdl-21938353
ABSTRACT
AIMS:
To determine if indirect testing for bronchial hyperresponsiveness (BHR) to monitor inhaled corticosteroid (ICS) treatment in asthma is feasible and acceptable in primary care.METHODS:
Fourteen adult patients with asthma aged 22-70 years (4M10F, forced expiratory volume in 1 s >70% predicted) taking ICS performed a test for BHR using mannitol on three visits 6 weeks apart. ICS dose adjustments were made based on the presence of BHR. The Asthma Quality of Life Questionnaire (AQLQ) and the Asthma Control Questionnaire were used at each visit. A semi structured interview at study exit assessed subject acceptability.RESULTS:
BHR did not return in those with no BHR at study entry (n=9) with decreasing ICS dose. Improvements in BHR with increasing ICS dose (n=5) were observed with clinically significant improvements in AQLQ (mean score increase >0.5, p=0.02). Feasibility and acceptability of BHR testing was demonstrated.CONCLUSIONS:
It is feasible and acceptable to perform BHR testing using mannitol to help identify patients with asthma who would benefit from ICS dose increases and those with no BHR who could have a dose reduction. TRIAL REGISTRATION Australia New Zealand Clinical Trial Registry ACTRN12610000807055.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Atenção Primária à Saúde
/
Asma
/
Testes de Provocação Brônquica
/
Broncoconstritores
/
Hiper-Reatividade Brônquica
/
Manitol
Tipo de estudo:
Clinical_trials
/
Prognostic_studies
/
Qualitative_research
Limite:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Ano de publicação:
2012
Tipo de documento:
Article